Clinical trials: Lymphomas,
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03037645
- Testing
- SNS-062
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Sunesis Pharmaceuticals
Nutritional and Metabolic Diseases
Rasburicase for Hyperuricemia
Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration.
- Trial name
- NCT00290992
- Testing
- rasburicase (SR29142)
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Sanofi
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination…
- Trial name
- ROMULUS (NCT01691898)
- Testing
- Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 231 people
- Sponsor
- Genentech, Inc.
Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.
- Trial name
- NCT02564744
- Testing
- Debio 1562, Rituximab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- Debiopharm International SA
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
- Trial name
- NCT04414163
- Testing
- IMC-001
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Colitis, Ulcerative
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- NCT00676832
- Testing
- COLAL-PRED
- Where
- 89 sites in United States
- Volunteers
- 190 people
- Sponsor
- Prometheus Laboratories
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready…
- Conditions
- Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
- Trial name
- QUADvance (NCT07284433)
- Testing
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
- Where
- 13 sites in United States, Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
RR DLBCL; PD-1; CD20
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
This is an open-label, single-arm, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of F520 (PD-1) combined with F007(rituximab biosimilar) in patients with Relapsed/Refractory diffuse large B-cell…
- Trial name
- NCT05178836
- Testing
- F520+F007
- Volunteers
- 62 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Cancer, Lymphomas
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages.
- Trial name
- NCT00396864
- Testing
- NPI-0052
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Celgene
Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations
Expanded Access to Ziftomenib
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with KMT2A…
- Conditions
- Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations, Acute Myeloid Leukemia, With KMT2A Rearrangements
- Trial name
- NCT05738538
- Testing
- ziftomenib
- Sponsor
- Kura Oncology, Inc.
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute…
- Trial name
- NCT00103701
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients…
- Conditions
- Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
- Trial name
- ACTION (NCT05352828)
- Testing
- Nivolumab, Autologous CD30.CAR-T, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tessa Therapeutics
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640…
- Trial name
- ABC-102 (NCT02229981)
- Testing
- ABC294640
- Where
- United States
- Sponsor
- RedHill Biopharma Limited
Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed…
- Trial name
- GLOBRYTE (NCT06084936)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for…
- Trial name
- NCT02077166
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 40 sites in United States, Belgium and 2 more
- Volunteers
- 138 people
- Sponsor
- Pharmacyclics LLC.
NSCLC (Non-small Cell Lung Cancer)
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase)…
- Trial name
- NCT01639001
- Testing
- Crizotinib, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 207 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Relapsed B-Cell Non Hodgkin Lymphoma
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
- Trial name
- NCT07125872
- Testing
- CD19 t-haNK- IV Administration
- Where
- 2 sites in South Africa
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.